Nystatin prophylaxis and treatment in severely immunodepressed patients

Abstract

DeGregorio 1982 {published data only} DeGregorio MW, Lee WM, Ries CA. Candida infections in patients with acute leukemia: ine ectiveness of nystatin prophylaxis and Nystatin prophylaxis and treatment in severely immunodepressed patients (Review)

Comparison of nystatin and fluconazole effects in the healing of oral candidiasis in immunocompromised individuals: A systematic review

“…But in case of potential resistance, fluconazole prophylaxis is limited to patients in whom prolonged and severe neutropenia and mucositis are expected. The daily dosage for the prophylaxis of these patients in the research is shown at least 8 mg / kg (22). The impact of the treatment of prophylaxis of fluconazole in the fungal colonization at neutropenic patients compared to the placebo group has shown that fluconazole reduces total number of ill patients and that its use is effective (23).…”

Comparison of nystatin and fluconazole effects in the healing of oral candidiasis in immunocompromised individuals: A systematic review

“…But in case of potential resistance, fluconazole prophylaxis is limited to patients in whom prolonged and severe neutropenia and mucositis are expected. The daily dosage for the prophylaxis of these patients in the research is shown at least 8 mg / kg (22). The impact of the treatment of prophylaxis of fluconazole in the fungal colonization at neutropenic patients compared to the placebo group has shown that fluconazole reduces total number of ill patients and that its use is effective (23).…”

Tratamiento odontológico en pacientes pediátricos sometidos a tratamiento oncológico. Artículo de revisión.

“…Pacientes sometidos a radioterapia y quimioterapia simultáneamente según Vega deberán contar con terapia profiláctica antifúngica por una o dos semanas previas al tratamiento oncológico, a través de antimicóticos con enjuagues o pastillas de nistatina. 56 La investigación realizada por Gotzache cataloga a la nistatina como un fármaco relativamente ineficaz ya que es casi insoluble y no se recomienda para el uso en pacientes con inmunodeficiencia grave, 57 en respaldo de este juicio Academia Americana de Odontopediatria coincide que la nistatina profiláctica no es eficaz en la prevención y tratamiento de infecciones fúngicas y recomienda realizar cultivos y biospsias de todas las lesiones sospechosas, para prescribir una terapia específica. 5 Nogal, evidenció que dentro de los métodos terapéuticos empleados en pacientes pediátricos que padecen de candidiasis orofaríngea, el uso del Fluconazol obtuvo mejores resultados que la Nistatina en suspensión, demostrando seguridad y tolerancia en niños con inmunodeficiencia.…”

Therapeutic tools for oral candidiasis: Current and new antifungal drugs

“…The choice of antifungal drug should take into account the patient immune status, the specific characteristics of oral candidiasis (clinical presentation, aetiology, susceptibility to antifungal drugs, organic location, dissemination) and the pharmacological characteristics of the available antifungal drugs (administration, metabolism, elimination, interactions with other drugs and toxicity). Three large families group the most commonly used anti- Nystatin perficial mycoses, such as flucytosine, griseofulvin and terbinafine, are not used commonly in oral candidiasis (7,8,11,(14)(15)(16)(17). Finally, other therapeutic alternatives under development involve the use of new antifungal drugs, terpens, probiotics, peptides with antifungal activity, sera with polyclonal or monoclonal antibodies or cocktails of cytokines (18)(19)(20)(21)(22)(23)(24)(25).…”

“…Although systemic azoles and echinocandins, with better tastes and less gastrointestinal adverse reactions, have provided new clinical options, topical therapy using nystatin (polyene) and miconazole (azole) are still the main recommended treatments for oral candidiasis due to its high efficacy, low cost, and less side effects, especially in low-income countries. The accumulated experience is important and their usefulness is clearly defined (7,8,(14)(15)(16)(17).…”

“…Treatment is effective only if nystatin is administered over a sufficient period. However, the unpleasant taste and this prolonged treatment pattern compromise compliance by the patient (11,14). The meta-analysis of Lyu X et al (8) showed that nystatin suspension and pastilles in combination for two weeks achieved a higher clinical and mycological cure rates, and using the nystatin pastilles alone might have a higher mycological cure rate, when compared with using nystatin suspensions alone.…”

Comparison of nystatin and fluconazole effects in the healing of oral candidiasis in immunocompromised individuals: A systematic review

“…But in case of potential resistance, fluconazole prophylaxis is limited to patients in whom prolonged and severe neutropenia and mucositis are expected. The daily dosage for the prophylaxis of these patients in the research is shown at least 8 mg / kg (22). The impact of the treatment of prophylaxis of fluconazole in the fungal colonization at neutropenic patients compared to the placebo group has shown that fluconazole reduces total number of ill patients and that its use is effective (23).…”

Tratamiento odontológico en pacientes pediátricos sometidos a tratamiento oncológico. Artículo de revisión.

“…Pacientes sometidos a radioterapia y quimioterapia simultáneamente según Vega deberán contar con terapia profiláctica antifúngica por una o dos semanas previas al tratamiento oncológico, a través de antimicóticos con enjuagues o pastillas de nistatina. 56 La investigación realizada por Gotzache cataloga a la nistatina como un fármaco relativamente ineficaz ya que es casi insoluble y no se recomienda para el uso en pacientes con inmunodeficiencia grave, 57 en respaldo de este juicio Academia Americana de Odontopediatria coincide que la nistatina profiláctica no es eficaz en la prevención y tratamiento de infecciones fúngicas y recomienda realizar cultivos y biospsias de todas las lesiones sospechosas, para prescribir una terapia específica. 5 Nogal, evidenció que dentro de los métodos terapéuticos empleados en pacientes pediátricos que padecen de candidiasis orofaríngea, el uso del Fluconazol obtuvo mejores resultados que la Nistatina en suspensión, demostrando seguridad y tolerancia en niños con inmunodeficiencia.…”

Therapeutic tools for oral candidiasis: Current and new antifungal drugs

“…The choice of antifungal drug should take into account the patient immune status, the specific characteristics of oral candidiasis (clinical presentation, aetiology, susceptibility to antifungal drugs, organic location, dissemination) and the pharmacological characteristics of the available antifungal drugs (administration, metabolism, elimination, interactions with other drugs and toxicity). Three large families group the most commonly used anti- Nystatin perficial mycoses, such as flucytosine, griseofulvin and terbinafine, are not used commonly in oral candidiasis (7,8,11,(14)(15)(16)(17). Finally, other therapeutic alternatives under development involve the use of new antifungal drugs, terpens, probiotics, peptides with antifungal activity, sera with polyclonal or monoclonal antibodies or cocktails of cytokines (18)(19)(20)(21)(22)(23)(24)(25).…”

“…Although systemic azoles and echinocandins, with better tastes and less gastrointestinal adverse reactions, have provided new clinical options, topical therapy using nystatin (polyene) and miconazole (azole) are still the main recommended treatments for oral candidiasis due to its high efficacy, low cost, and less side effects, especially in low-income countries. The accumulated experience is important and their usefulness is clearly defined (7,8,(14)(15)(16)(17).…”

“…Treatment is effective only if nystatin is administered over a sufficient period. However, the unpleasant taste and this prolonged treatment pattern compromise compliance by the patient (11,14). The meta-analysis of Lyu X et al (8) showed that nystatin suspension and pastilles in combination for two weeks achieved a higher clinical and mycological cure rates, and using the nystatin pastilles alone might have a higher mycological cure rate, when compared with using nystatin suspensions alone.…”

Comparison of nystatin and fluconazole effects in the healing of oral candidiasis in immunocompromised individuals: A systematic review

“…But in case of potential resistance, fluconazole prophylaxis is limited to patients in whom prolonged and severe neutropenia and mucositis are expected. The daily dosage for the prophylaxis of these patients in the research is shown at least 8 mg / kg (22). The impact of the treatment of prophylaxis of fluconazole in the fungal colonization at neutropenic patients compared to the placebo group has shown that fluconazole reduces total number of ill patients and that its use is effective (23).…”

Tratamiento odontológico en pacientes pediátricos sometidos a tratamiento oncológico. Artículo de revisión.

“…Pacientes sometidos a radioterapia y quimioterapia simultáneamente según Vega deberán contar con terapia profiláctica antifúngica por una o dos semanas previas al tratamiento oncológico, a través de antimicóticos con enjuagues o pastillas de nistatina. 56 La investigación realizada por Gotzache cataloga a la nistatina como un fármaco relativamente ineficaz ya que es casi insoluble y no se recomienda para el uso en pacientes con inmunodeficiencia grave, 57 en respaldo de este juicio Academia Americana de Odontopediatria coincide que la nistatina profiláctica no es eficaz en la prevención y tratamiento de infecciones fúngicas y recomienda realizar cultivos y biospsias de todas las lesiones sospechosas, para prescribir una terapia específica. 5 Nogal, evidenció que dentro de los métodos terapéuticos empleados en pacientes pediátricos que padecen de candidiasis orofaríngea, el uso del Fluconazol obtuvo mejores resultados que la Nistatina en suspensión, demostrando seguridad y tolerancia en niños con inmunodeficiencia.…”

Therapeutic tools for oral candidiasis: Current and new antifungal drugs

“…The choice of antifungal drug should take into account the patient immune status, the specific characteristics of oral candidiasis (clinical presentation, aetiology, susceptibility to antifungal drugs, organic location, dissemination) and the pharmacological characteristics of the available antifungal drugs (administration, metabolism, elimination, interactions with other drugs and toxicity). Three large families group the most commonly used anti- Nystatin perficial mycoses, such as flucytosine, griseofulvin and terbinafine, are not used commonly in oral candidiasis (7,8,11,(14)(15)(16)(17). Finally, other therapeutic alternatives under development involve the use of new antifungal drugs, terpens, probiotics, peptides with antifungal activity, sera with polyclonal or monoclonal antibodies or cocktails of cytokines (18)(19)(20)(21)(22)(23)(24)(25).…”

“…Although systemic azoles and echinocandins, with better tastes and less gastrointestinal adverse reactions, have provided new clinical options, topical therapy using nystatin (polyene) and miconazole (azole) are still the main recommended treatments for oral candidiasis due to its high efficacy, low cost, and less side effects, especially in low-income countries. The accumulated experience is important and their usefulness is clearly defined (7,8,(14)(15)(16)(17).…”

“…Treatment is effective only if nystatin is administered over a sufficient period. However, the unpleasant taste and this prolonged treatment pattern compromise compliance by the patient (11,14). The meta-analysis of Lyu X et al (8) showed that nystatin suspension and pastilles in combination for two weeks achieved a higher clinical and mycological cure rates, and using the nystatin pastilles alone might have a higher mycological cure rate, when compared with using nystatin suspensions alone.…”